Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Olysio/Sovaldi yield high SVR post-liver transplant

In a retrospective study, a combination treatment regimen of Olysio and Sovaldi led to high sustained virologic response rates among patients with hepatitis C virus infection post-liver transplant and with advanced liver disease.

Published
4 hours ago
From
Healio
Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance

The Fair Pricing Coalition (FPC) today expressed appreciation for Merck’s & Co. Inc.’s decision to launch its new curative hepatitis C (HCV) treatment, Zepatier, at a price below existing HCV treatments in a tacit acknowledgement that existing high prices have hurt patients and are untenable for the market. Zepatier’s $54,600 list price is lower than the egregious prices for Gilead Sciences’ Harvoni ($94,500) and AbbVie’s Viekira Pak ($83,319), and represents a step in the right direction.

Published
4 hours ago
From
Fair Pricing Coalition
U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Updated label provides new treatment option for patients with HIV-1 coinfection, advanced cirrhosis, and post-liver transplant HCV recurrence.

Published
4 hours ago
From
Bristol-Myers Squibb press release
Pennsylvania to Offer Free Hepatitis C Treatment to Low-Income People With HIV

The $13 million, six-month program  is expected to aid hundreds of low-income people over 65 years old in the state.

Published
05 February 2016
From
Poz magazine news
Lawsuits claim insurers unfairly refuse pricey hepatitis C drugs

Two Washington state insurers — Group Health Cooperative and BridgeSpan — are targeted in class-action lawsuits that claim the companies are unfairly rationing new drugs that can cure hepatitis C based on high cost, not medical need.

Published
03 February 2016
From
Seattle Times
Lawmaker: Costly hepatitis C drug "a slap in the face to veterans"

A Congressional hearing will begin Wednesday in response to a CBS News investigation, where we showed how a costly new cure for hepatitis C isn't making it to most of the 200,000 U.S. veterans infected with the disease, many as a result of their service. Congress has given $2.7 billion taxpayer to treat veterans with hepatitis C, but only 15 percent have been treated with the drug, one that might not exist without government funding.

Published
03 February 2016
From
CBS News
Merck Throws a Wrench in Drug Pricing

Volume may help Merck make up what it loses on price. AbbVie and Gilead's drugs are priced so high that many governments and insurers will only pay for them for patients that have severe liver scarring, given HCV's slow progression. Zepatier is priced at a point that could make it affordable to treat a much larger population at earlier stages of the disease.

Published
01 February 2016
From
Bloomberg
New Merck combination pill Zepatier approved for hepatitis C treatment in the United States

Merck has received a US license for its direct-acting antiviral combination of grazoprevir and elbasvir, to be marketed as Zepatier. The combination of grazoprevir (an HCV protease inhibitor)

Published
01 February 2016
By
Keith Alcorn
Zepatier for hepatitis C approved in Canada

On January 19, 2016, Health Canada licensed the use of Zepatier for the treatment of certain strains of hepatitis C virus (HCV) in adults. Canada is the first country to approve Zepatier. This drug is made by the pharmaceutical company Merck and should be available for order by drug stores early in February 2016.

Published
01 February 2016
From
CATIE
European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV

Updated label provides additional treatment options for multiple HCV patient populations, including difficult-to-treat patients with decompensated cirrhosis.

Published
01 February 2016
From
Bristol-Myers Squibb press release
← First12345...189Next →

Filter by country